[ad_1]
One of the COVID-19 vaccines currently being tested is even more effective than experts dared to believe beforehand.
Pharmaceutical manufacturer Pfizer and its German partner Biontech claim that the latest crucial phase 3 studies tentatively show that the vaccine protects up to 90 percent.
This means that nine out of ten who receive the vaccine develop immunity.
It has been speculated beforehand that 50 percent protection might be acceptable to approve the vaccine.
43,000 have been tested
In phase 3, the new drug is being tested in large patient groups of several hundred or perhaps several thousand people.
If the phase 3 studies are successful, you can request approval of the treatment from the authorities.
The Pfizer vaccine trial included more than 43,000 people.
No side effects
No side effects have been reported, Pfizer said.
“This is good news,” said Danny Altmann, professor of immunology at Imperial College London.
But he notes that the new vaccines must be approved by authorities and delivered to people around the world and that it will take months.
If all goes well, the authorities will be able to pronounce on this vaccine at the end of November. If the vaccine is approved, it can be released for medical attention by the end of the year.
About 10 different alternatives to the covid-19 vaccine have reached the phase 3 testing stage.
EU cooperation on vaccine trade
The EU is cooperating in the purchase of vaccines so that the EU countries have a negotiating triumph based on a large number of orders in a difficult market situation.
The Commission negotiates vaccine advances with vaccine manufacturers. The EU is also committed to international solidarity to promote equal access to vaccines.
The EU advance purchase agreement is funded through the EU emergency fund, which includes all 27 member states.
The EEU (Eurasian Economic Union) has concluded a preliminary agreement on the procurement of vaccines with the company AstraZeneca.
The EEU has also entered into an agreement to purchase vaccines from SanofiPasteur-GSK and has initiated initial negotiations with Johnson & Johnson, BionTech / Pfizer, Moderna and Curevaci.
Negotiations with other manufacturers are also underway. The agreements are between the Commission and the companies and are secret.
The vaccine must be included in the national vaccine program.
According to the Ministry of Social Affairs and Health, the coronavirus vaccine must be included in the national vaccination program. The vaccine must be voluntary and free. The vaccine will be administered to the entire population.
Those who are likely to get vaccinated first are people with professional training in the field of health and social care, as well as workers who are in a key position with respect to the basic functions of society.
The former are vaccinated first so that they are healthy and can maintain the viability of healthcare.
Additionally, the first to be vaccinated include medically defined risk groups who are at higher risk of developing a severe form of COVID-19 disease compared to others, and people who are at higher risk due to their age.
Stock market recovery after the news
Stock markets are heading higher on news of the corona vaccine. In particular, the value of the shares of companies most affected by the coronavirus has gained momentum.
On the Helsinki Stock Exchange, Finnair’s share value increased by 23 percent and the value of restaurant company NoHo Partners by 19 percent on Monday afternoon.
The main index of the Helsinki Stock Exchange was 3.64 percent on the upside. The shares of many airlines are also rising in value, including Ryanairs.
The article was updated at 4:17 p.m. with the last three intermediate headings dealing with EU cooperation on vaccines, information from the Ministry of Social Affairs and Health on who gets the vaccine first and that stock market prices point towards up after the news.
